Mirikizumab met the primary and all key secondary endpoints in LUCENT-1, phase III induction study to evaluate the efficacy and safety of mirikizumab for moderate to severe ulcerative colitis .
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest